Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Accumulated Expenses: 2021-2025

Historic Other Accumulated Expenses for Relay Therapeutics (RLAY) over the last 4 years, with Sep 2025 value amounting to $1.1 million.

  • Relay Therapeutics' Other Accumulated Expenses fell 20.50% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 20.50%. This contributed to the annual value of $2.0 million for FY2024, which is 65.28% up from last year.
  • As of Q3 2025, Relay Therapeutics' Other Accumulated Expenses stood at $1.1 million, which was up 77.01% from $609,000 recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Other Accumulated Expenses registered a high of $26.9 million during Q3 2022, and its lowest value of $396,000 during Q4 2021.
  • In the last 3 years, Relay Therapeutics' Other Accumulated Expenses had a median value of $1.4 million in 2024 and averaged $5.7 million.
  • Per our database at Business Quant, Relay Therapeutics' Other Accumulated Expenses surged by 6,504.04% in 2022 and then crashed by 96.96% in 2024.
  • Relay Therapeutics' Other Accumulated Expenses (Quarterly) stood at $396,000 in 2021, then soared by 6,504.04% to $26.2 million in 2022, then slumped by 95.40% to $1.2 million in 2023, then soared by 65.28% to $2.0 million in 2024, then decreased by 20.50% to $1.1 million in 2025.
  • Its Other Accumulated Expenses stands at $1.1 million for Q3 2025, versus $609,000 for Q2 2025 and $1.7 million for Q1 2025.